Summary

for people ages 18 years and up (full criteria)
at UCLA
study started
estimated completion
Martin Allen-Auerbach(ucla)

Description

Summary

This pilot trial studies how well fluorine F 18 clofarabine positron emission tomography (PET)/computed tomography (CT) works in imaging patients with autoimmune or inflammatory diseases. Fluorine F 18 clofarabine is an imaging agent or tracer which may be taken up by inflammatory tissue in the body. Diagnostic imaging, such as PET/CT scans, can be used to measure the amount of injected tracer that is taken up by inflammatory tissue. PET/CT scan may help to determine how fluorine F 18 clofarabine is distributed throughout the body.

Official Title

The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases

Details

PRIMARY OBJECTIVES:

  1. Determine how fluorine F 18 clofarabine (18F‐clofarabine) is distributed in the body, in patients with autoimmune and inflammatory diseases.

II. Determine whether 18F‐clofarabine can be used to image patients with autoimmune and inflammatory diseases.

OUTLINE:

Patients receive fluorine F 18 clofarabine intravenously (IV) and undergo a single PET/CT scan for up to 120 minutes.

Keywords

Autoimmune Disease Crohn Disease Inflammatory Disorder Rheumatoid Arthritis Systemic Lupus Erythematosus Takayasu Arteritis Arteritis Aortic Arch Syndromes Lupus Erythematosus, Systemic Autoimmune Diseases Clofarabine Fluorides Computed Tomography Fluorine F 18 Clofarabine Positron Emission Tomography Imaging (fluorine F 18 clofarabine, PET/CT)

Eligibility

You can join if…

Open to people ages 18 years and up

  • Must be 18 years or older.
  • Diagnosed with an autoimmune and inflammatory disorder.

You CAN'T join if...

  • Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge.
  • Patients unable to undergo or comply with PET/CT scanning due to pre-existing medical conditions including claustrophobia.

Location

  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles California 90095 United States

Lead Scientist

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT02925351
Study Type
Interventional
Last Updated